Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eGPA and local inflammation within the ENT area; Impact of Mepolizumab on nasal microbiome and immune response
2023-508029-28-00Phase 4Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA), asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and 1 more (5 arms), sponsored by University Medical Center Groningen. Primary endpoint: Change in nasal microbiome profiles after mepolizumab treatment. Planned start Feb 2024; status: authorised.
02
Drugs
mepolizumab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)asthmachronic rhinosinusitis with nasal polyps (CRSwNP)granulomatosis with polyangiitis (GPA)
Beyond the preview
Go deeper on 2023-508029-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508029-28-00.